SCHEMBL370510

SCHEMBL370510

C=CCOc1nn(Cc2ccc(OC)cc2)cc1C(=O)N(C)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.39
AADAT Q8N5Z0 1/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 2/20 0.38
GAA P10253 1/20 0.38
CACNA1G O43497 2/20 0.38
CACNA1H O95180 2/20 0.38
CACNA1I Q9P0X4 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TSPO P30536 2/20 0.35
CYP19A1 P11511 1/20 0.35
HDAC1 Q13547 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370874 0.86 FLT3 (0.42) FLT3AADATKMT2AKDM4EALDH1A1
SCHEMBL370237 0.86 KMT2A (0.47) FLT3AADATKMT2AKDM4EALDH1A1
SCHEMBL368884 0.85 BLM (0.42) FLT3AADATKMT2AKDM4EALDH1A1
SCHEMBL369366 0.83 CACNA1G (0.40) AADATKMT2AALDH1A1MEN1CACNA1G
SCHEMBL369326 0.82 CACNA1G (0.40) AADATKMT2AALDH1A1MEN1CACNA1G
SCHEMBL370661 0.81 KDM4E (0.43) KMT2AKDM4EALDH1A1HPGDMEN1
SCHEMBL369221 0.81 CACNA1G (0.41) AADATKMT2AALDH1A1MEN1CACNA1G
SCHEMBL368790 0.81 KLKB1 (0.47) AADATKLKB1
SCHEMBL370679 0.80 L3MBTL1 (0.44) AADATKMT2AALDH1A1MEN1CACNA1G
SCHEMBL370299 0.79 AADAT (0.43) AADATKMT2AKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 FLT3 1198/4885AADAT 837/4885KMT2A 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.